1,2 The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company ... of progression-free survival (PFS ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

“Eli Lilly and Company (NYSE:LLY) is a global pharmaceutical company with core franchises in diabetes, obesity, neurology, and oncology. Its portfolio includes innovative drugs like ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

According to Twitter ... Eli Lilly became a part of this group, after an account using its name and logo sent out a Tweet, which read: “We are excited to announce insulin is free now.” ...

Restaurant Mama’s Kitchen is among awardees from across the country who received a special grant from Direct Relief’s Fund ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly's innovative culture ... hold major blockbuster potential. Lilly's strong entrenchment in insulin production should also help the company deal with patent losses. Unlike traditional ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly (LLY) stock rises as company posts Q4 2024 results, beating expectations with a twofold rise in revenue from weight ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...